Provision of a Framework Agreement for Nuclear Medicine Radiopharmacy Services and Consumables

University College London Hospitals NHS Foundation Trust (the "Authority"), is issuing this tender in connection with a Competitive with Negotiation Procedure Procurement for the Provision of a Framework Agreement for Nuclear Medicine Radiopharmacy Services and Consumables for University College London Hospitals NHS Foundation Trust (the "Contract"), and the subsequent call off of Radiopharmacy Services and Consumables(the "Call Offs") from the Contract by the Authority. This procurement and resulting single supplier Framework Agreement contains three lots: Lot 1: UCLH Managed Services Lot 2: Managed Services Lot 3: Radiopharmaceutical Consumables The highest scoring supplier will be awarded all three lots, resulting in a single supplier Framework Agreement.Where the Authority wishes to call off from this Framework Agreement, a separate contract will be entered into for the services under each lot. The Framework Agreement will be available to the Authority and all other NHS Trusts. For a detailed list of all NHS Trusts please see https://www.nhs.uk/servicedirectories/pages/nhstrustlisting.aspx. UCLH provides first-class acute and specialist services in six hospitals in central London. During 2019 and 2020 UCLH will be opening two new hospital sites: Opening in September 2019, a specialist centre for services currently at the Eastman Dental and Royal National Throat Nose and Ear Hospitals.Opening in 2020, a new facility which includes Europe's largest centre for blood disorders, short stay surgery and a national proton beam therapy centre. Further information relating to the non-PFI estate can be found in the data pack issued with this ITPN and in the Service Matrix. The Institute of Nuclear Medicine (INM) carries out radionuclide imaging investigations and therapies for the purposes of clinical diagnosis, treatment and research. It is the largest single site department in the UK and currently undertakes some 17,000 studies per annum. INM provide a wide range of "state of the art" nuclear medicine imaging services including: • General nuclear medicine including in-vitro tests; • Single-Photon Emission Computed Tomography (SPECT) / with x-ray Computed Tomography (CT) (SPECT/CT); • Ultra-fast dedicated cardiac SPECT; • Positron Emission Tomography/Computed Tomography (PET/CT); • Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) (first in the UK) In addition, INM also perform a range of routine and experimental inpatient and outpatient radionuclide therapy procedures, with access to ten dedicated radionuclide therapy beds. The Authority is looking to enter into a new contract that is able to provide an innovative and flexible approach. It is seen as imperative that there is an on-site element to this contract in order to maintain an efficient and effective working partnership with tangible benefits for both parties. In particular certain isotopes would continue to benefit form on site production due to their limited shelf life.